Isis Pharmaceuticals, Inc.

National University of Singapore

Ian Popoff

Jacqueline R Wyatt

Lex M Cowsert

Susan M Freier

Brett P Monia

Kenneth W Dobie

James G Karras

Vickie L Brown-Driver

Wai Shiu Fred Wong

Compositions and methods for the treatment and diagnosis of diseases or conditions amenable to treatment through modulation of expression of a gene encoding a p38 mitogen-activated protein kinase (p38 MAPK) are provided. Methods for decreasing airway hyperresponsiveness or airway inflammation in an animal are also provided.

Antisense modulation of p38 mitogen activated protein kinase expression

Antisense compounds, compositions and methods are provided for modulating the expression of Damage-specific DNA binding protein 1, p127. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Damage-specific DNA binding protein 1, p127. Methods of using these compounds for modulation of Damage-specific DNA binding protein 1, p127 expression and for treatment of diseases associated with expression of Damage-specific DNA binding protein 1, p127 are provided.

Antisense modulation of damage-specific DNA binding protein 1, p127 expression

Antisense compounds, compositions and methods are provided for modulating the expression of PTPN2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTPN2. Methods of using these compounds for modulation of PTPN2 expression and for treatment of diseases associated with expression of PTPN2 are provided.

Antisense modulation of PTPN2 expression

Antisense compounds, compositions and methods are provided for modulating the expression of human PARP. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding human PARP. Methods of using these compounds for modulation of human PARP expression and for treatment of diseases associated with expression of human PARP are provided.

Antisense modulation of PARP expression

Antisense compounds, compositions and methods are provided for modulating the expression of Damage-specific DNA binding protein 2, p48. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Damage-specific DNA binding protein 2, p48. Methods of using these compounds for modulation of Damage-specific DNA binding protein 2, p48 expression and for treatment of diseases associated with expression of Damage-specific DNA binding protein 2, p48 are provided.

Antisense modulation of damage-specific DNA binding protein 2, p48 expression

Antisense compounds, compositions and methods are provided for modulating the expression of E2F transcription factor 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding E2F transcription factor 1. Methods of using these compounds for modulation of E2F transcription factor 1 expression and for treatment of diseases associated with expression of E2F transcription factor 1 are provided.

Antisense inhibition of e2f transcription factor 1 expression

Antisense compounds, compositions and methods are provided for modulating the expression of E2F transcription factor 3. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding E2F transcription factor 3. Methods of using these compounds for modulation of E2F transcription factor 3 expression and for treatment of diseases associated with expression of E2F transcription factor 3 are provided.

Growing community of inventors

Encinitas, CA, United States of America

Ian Popoff